HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

被引：0
|
作者：
Catalina Falo
Abelardo Moreno
Mar Varela
Belen Lloveras
Agnès Figueras
Agustín Escobedo
机构：
[1] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[2] Hospital Universitari de Bellvitge,Department of Medical Oncology, Breast Cancer Unit, Institut Català d’Oncologia
[3] Hospital Duran i Reynals,Department of Pathology, Breast Cancer Unit
[4] Hospital Universitari de Bellvitge,Tumour Bank, Institut Català d’Oncologia
[5] Hospital Duran i Reynals,Department of Pathology, Institut Català d’Oncologia
[6] Hospital Duran i Reynals,Translational Research Laboratory, Institut Català d’Oncologia
[7] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[8] Hospital Duran i Reynals,Unitat Funcional de Mama
[9] Institut Català d’Oncologia,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2007年 / 133卷
关键词：
Breast carcinoma; Her-2/; Primary chemotherapy; Response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：423 / 429
页数：6
相关论文
共 50 条
  • [41] Upregulation of HER-2/neu by ovarian ablation:: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients
    Lüftner, D
    Jung, A
    Schmid, P
    Geppert, R
    Kienle, E
    Wernecke, KD
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (03) : 245 - 255
  • [42] ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER USING CMFVP VS CMF VS CMF-MER - A CALGB STUDY
    WEISS, RB
    KORZUN, AH
    TORMEY, DC
    HOLLAND, JF
    WEINBERG, VE
    WOOD, WC
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) : 339 - 339
  • [43] Preliminary study of serum HER-2/neu detection in primary breast cancer patients.
    Thriveni, K.
    Deshmane, V
    Bapsy, P. P.
    Krishnamoorthy, L.
    Kidwai, Ramaswamy G.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S41
  • [44] FOLLOW-UP-STUDY OF HER-2/NEU AMPLIFICATION IN PRIMARY BREAST-CANCER
    CLARK, GM
    MCGUIRE, WL
    CANCER RESEARCH, 1991, 51 (03) : 944 - 948
  • [45] Amplification of HER-2/neu and Topoisomerase IIα in primary and metastatic breast cancer
    Tanner, M
    Järvinen, P
    Isola, J
    CANCER RESEARCH, 2001, 61 (14) : 5345 - 5348
  • [46] Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
    Simon, R
    Nocito, A
    Hübscher, T
    Bucher, C
    Torhorst, J
    Schraml, P
    Bubendorf, L
    Mihatsch, MM
    Moch, H
    Wilber, K
    Schötzau, A
    Kononen, J
    Sauter, G
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (15) : 1141 - 1146
  • [47] Evaluation of Serum HER-2/neu Extracelluar Domain in Breast Cancer Patients: Correlation with Tissue HER-2/neu Status and Clinicopathological Factors
    Kang, Sun Hee
    Cho, Jihyoung
    Ha, Jung Sook
    Kwon, Sun Young
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2010, 78 (05): : 271 - 276
  • [48] Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status
    Wang, SJ
    Saboorian, MH
    Frenkel, EP
    Haley, BB
    Siddiqui, MT
    Gokaslan, S
    Hynan, L
    Ashfaq, R
    MODERN PATHOLOGY, 2002, 15 (02) : 137 - 145
  • [49] HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer
    Dresse, M.
    Mayr, D.
    Heinemann, V.
    Kahlert, S.
    Bauerfeind, I.
    Nagel, D.
    Seidel, D.
    Stieber, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] HER-2/NEU IN TISSUE AND SERUM AT TIME OF PRIMARY DIAGNOSIS OF BREAST CANCER
    Dresse, M.
    Mayr, D.
    Heinemann, V.
    Kahlert, S.
    Bauerfeind, I.
    Nagel, D.
    Seidel, D.
    Stieber, P.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4027 - 4027
12345